Compugen Ltd.

Compugen Ltd. is a clinical-stage biopharmaceutical company whose core business involves developing therapeutic antibodies. This drug discovery and development process inherently requires animal testing for preclinical research and regulatory compliance. The company’s pipeline candidates, including immuno-oncology therapies, are advanced through stages that typically involve in vivo studies using animal models.

While the provided evidence does not detail specific violations by Compugen, the company operates within an industry sector where animal testing is a standard, material component of the business model. The nature of its work—developing novel biological therapeutics—relies on animal data to demonstrate safety and efficacy before human trials. This places the company within the broad commercial exploitation of animals for research purposes, which is captured under this exclusion category.